As Eli Lilly ends the year with Zepbound in good supply, TD Cowen analyst Steve Scaliaasked CEO David Ricks if the company ...

January 2025 kicked off with a wave of impactful biotech deals, setting the stage for an exciting year of innovation.

The 90 million euros ($94 million) raised by Orbis Medicines in a series A round was not January’s biggest venture investment ...

The discontinuation comes after the investigational drug, volenrelaxin, failed a related heart failure study in an ...

A new study led by Western researchers found frequent treatment with intranasal oxytocin – a hormone in the brain associated ...

Eli Lilly and Co. reported that its FDA-approved weight-loss drug Zepbound (tirzepatide) outperformed Novo Nordisk A/S’s Wegovy (semaglutide) in the phase IIIb Surmount-5 trial.

Eli Lilly and venture capital firm Andreessen Horowitz ... s R&D expertise to “foster a technology ecosystem of ambitious bio + health entrepreneurs and innovators,” according to a Jan ...

In an apparently unprecedented move, Eli Lilly is partnering with the fabled ... Vineeta Agarwala, a partner at Andreessen’s biotech arm, a16z Bio + Health, said the deal aims to combine ...

Andreessen Horowitz noted on the 10th (local time) that it will collaborate with Eli Lilly to create the first venture capital fund aimed at promoting extensive innovation in the bio sector.

Bio + Health today announced a newly formed, first-of-its-kind venture capital fund to fuel broader innovation in human health, in partnership with Eli Lilly and Company (“Lilly”). The Biotech ...